Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Augusto Villegas

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Journal of Thoracic Oncology

English

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy

Case Reports in Oncological Medicine

Oncology

2017

English

Related publications

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

Journal of Thoracic Oncology

English

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Journal of Thoracic Oncology

English

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

Clinical Cancer Research

Cancer Research

Oncology

2011

English

Favorable Response to Pembrolizumab After Durvalumab Failure in a Stage III Sarcomatoid Carcinoma of the Lung: A Case Report

BMC pharmacology & toxicology

Medicine

Pharmacology

2020

English

Durvalumab Extends OS in NSCLC

Cancer Discovery

Oncology

2018

English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology

English

Better Overall Survival With Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis

International Journal of Radiation Oncology Biology Physics

English

Pre-Treatment CT Radiomics to Predict 3-Year Overall Survival Following Chemoradiotherapy of Esophageal Cancer

English

PD-L1-Antikörper Durvalumab Verlängert Überleben Bei NSCLC Im Stadium III

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Augusto Villegas

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy

Related publications

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

Favorable Response to Pembrolizumab After Durvalumab Failure in a Stage III Sarcomatoid Carcinoma of the Lung: A Case Report

Durvalumab Extends OS in NSCLC

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Better Overall Survival With Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis

Pre-Treatment CT Radiomics to Predict 3-Year Overall Survival Following Chemoradiotherapy of Esophageal Cancer

PD-L1-Antikörper Durvalumab Verlängert Überleben Bei NSCLC Im Stadium III